Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EDQM surveys industry on RO for WFI

This article was originally published in The Gold Sheet

Executive Summary

Should the European Pharmacopoeia let drug makers use reverse osmosis to produce water for injection? The European Directorate for the Quality of Medicines and Healthcare said April 1 that it is surveying industry on this question. EP requires distillation, while the U.S. Pharmacopeia allows reverse osmosis, although FDA imposes strict controls on it. The European Medicines Agency summarized the objections in a March 5, 2008, reflection paper: reverse osmosis cannot screen out contaminants smaller than water molecules, such as chlorine or volatile organic chemicals; and the reverse osmosis membrane can become, in effect, a bacterial fermenter by allowing a biofilm to form on its upstream side and possibly spread to the permeate side or secrete metabolic byproducts that could pass through the membrane. Reverse osmosis would be cheaper and more practical, and some say new technologies would make it safe. Responses are due May 30

You may also be interested in...

EMA Proposal Would Give Popular Alternative For Pharmaceutical Water A Foothold in Europe

The European Medicines Agency is inviting stakeholder feedback on a proposal to allow reverse osmosis as an alternative to steam distillation for making water for injections (WFI) for pharmaceutical manufacturing. EMA also would expand its water quality guideline to cover vaccines and advanced therapy medicinal products such as cell and gene therapies.

Compounding Pharmacies Sue FDA For Conflating Out-Of-State Dispensing And Distribution In MOU

Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.

What COVID Spotlight Means For Pharma – In Their Own Words

Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem. 




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts